DNA methylation-the covalent addition of methyl groups to nucleotide bases, most 44 often at CpG motifs-is a gene regulatory mechanism that plays a fundamental role in 45 development, disease susceptibility, and the response to environmental conditions 1-6 . These 46 functions suggest that variation in DNA methylation should be important in explaining trait 47 variation. In support of this idea, epigenome-wide association studies (EWAS) have now 48 identified thousands of statistical relationships between phenotypic variation and DNA 49 methylation levels at individual CpG sites across the genome 7 . 50
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Abstract: 29 Changes in DNA methylation are important in development and disease, but not all 30 regulatory elements act in a methylation-dependent (MD) manner. Here, we developed 31 mSTARR-seq, a high-throughput approach to quantify the effects of DNA methylation on 32 regulatory element function. We assay MD activity in 14% of the euchromatic human genome, 33 identify 2,143 MD regulatory elements, and predict MD activity using sequence and chromatin 34 state information. We identify transcription factors associated with higher activity in 35 unmethylated or methylated states, including an association between pioneer transcription factors 36 and methylated DNA. Finally, we use mSTARR-seq to predict DNA methylation-gene 37 expression correlations in primary cells. Our findings provide a map of MD regulatory activity 38 across the human genome, facilitating interpretation of the many emerging associations between 39 methylation and trait variation. 40 41 42 these regions to focus on the 277,896 intervals that overlapped at least 1 mRNA read and 1 DNA 89 read in at least half of the replicates in each condition. These 277,896 intervals were covered by 90 724,391 unique fragments of size 314 bp ± 105 bp (mean ± S.D.; fig. S3 ). This stringently 91 filtered data set represents 1.83 million unique CpG sites, 57% of fragments expected from a 92
complete MspI digest of the human genome, and 14% of the euchromatic genome of the K562 93 cell line ( fig. S4 ). 94 We first focused on regions with regulatory capacity (i.e., enhancer-like activity), 95 whether in the unmethylated condition, methylated condition, or both. We identified 24,945 96 intervals of 200 bp (9% of analyzed regions, at a 10% false discovery rate) in which the 97 abundance of plasmid-derived mRNA was significantly greater than the amount of input plasmid 98
DNA (Table S3 ). As expected, the set of regions capable of enhancer-like activity was highly 99 enriched for K562 ENCODE chromatin states 19 associated with H3K4me1 and H3K27ac, which 100 mark active enhancers (Fisher's exact test, log 2 odds=2.53, p<10 -15 ) and highly depleted in 101 regions that lacked both marks (log 2 odds=-0.94, p<10 -15 ; Fig. 2A ). Regions that overlapped 102
H3K4me1 and H3K27ac-marked chromatin states also consistently displayed the largest effect 103 sizes (relative to regions that lacked these marks, or only exhibited one mark; linear model, 104
p<10 -15 ; Fig. 2B ). Finally, regions annotated as strong enhancers in K562 cells exhibited the 105 strongest effects of all 12 chromatin states (p<10 -15 ), and contained the largest proportion of 106 elements with significant regulatory activity relative to any other chromatin state (at a 10% FDR, 107 37% of regions tested had significant activity). In general, power to detect enhancer activity 108 increased with larger query fragment sizes ( Fig. 2C ), suggesting that short fragments may 109 eliminate binding sites key to functional enhancer activity. 110 We next investigated which regulatory elements were functionally affected by DNA 111 methylation marks. We identified 2,143 regions with significant MD activity (8.59% of those 112 tested; 10% FDR), 88% of which were more active when unmethylated and 12% which were 113 more active when methylated ( Fig. 3A ; Table S4 ). Only 4 of the 941 CpG-free regions in the 114 analysis set (0.4%) were inferred to have MD activity, indicating a low false positive rate ( Fig.  115 3B). Estimates of MD activity from mSTARR-seq were also consistent with estimates from 116 single-locus luciferase reporter assays 13 (Fig. 1E ). Overall, we found that MD enhancers have 117
higher CpG densities and contain more CpG sites than non-MD enhancers (Wilcoxon-signed  118 rank test, W=3.51x10 7 , p<10 -15 ; Fig. 3C ). However, CpG density only explained 6.8% of 119 variation in the magnitude of methylation dependence, suggesting that other characteristics also 120 contribute to quantitative variation in MD activity (Spearman's rho=0.246, p<10 -15 ; Fig. 3D ). 121
To explore these characteristics, we used a random forests classifier to evaluate the 122 contribution of 147 genomic features to differentiating MD enhancers (specifically, the n=1866 123 regions suppressed by methylation) from non-MD enhancers (n=5703 regions that exceed an 124 FDR of 50% in our test for MD activity (Table S5 ).
127
The resulting RF model predicted MD regulatory element activity with 82% accuracy (Fig. 3E ). 128
In addition to CpG site information, 25 features were identified as key predictors based on two 129 measures of variable importance, the mean decrease in accuracy and the Gini coefficient 130 (FDR<10%; Fig. 3 and Table S5 ). Relative to non-MD enhancers, enhancers suppressed by 131
DNA methylation were more likely to occur in regions with endogenous promoter activity and 132 less likely to occur in endogenously repressed regions of the genome. MD enhancers were also 133 more likely to contain binding sites for the TFs ELF1, E2F6, MAX, and MYC, all of which have 134
CpG sites in their canonical binding motifs ( Fig. 3F ). 135 Previous work indicates that many TFs are sensitive to DNA methylation levels in or near 136 their binding motifs 15-17 . This ability to "read" epigenetic modifications to DNA sequence could 137 explain, at least in part, variation in MD regulatory activity in our data set. Indeed, among the 138 1866 MD enhancers in which DNA methylation suppresses activity, we identified 24 139 significantly enriched TF binding motifs (relative to the background set of all regions with 140 mSTARR-seq regulatory activity; 1% FDR). 15 of these motifs belong to the ETS family, a 6.6x 141 enrichment over chance (hypergeometric test p=3x10 -13 ; Fig. 4A and Table S6 ). ETS binding is 142 thought to be methylation dependent for 'Class I' ETS TFs [22] [23] [24] [25] [26] [27] , which bind the canonical motif 143
ACCGGAAGT, but not for 'Class III' ETS family TFs, whose binding motifs do not consistently 144
include CpG sites 28 . In support, 12 of the 15 ETS TFs we identified belong to Class I, and none 145 belong to Class III. The remaining 3 belong to Class II, for which methylation-dependent binding 146 was previously unexplored: our results suggest they behave more similarly to Class I than Class 147 III. 148
We also identified 9 significantly enriched TF binding motifs in the 257 MD enhancers 149 with increased activity in the methylated condition (1% FDR). TFs from the basic helix-loop-150 helix (bHLH) family and GATA subfamily of zinc finger TFs were strongly enriched in this set 151 (a 2.91x and 20x enrichment over chance, hypergeometric test p=0.33 and p=1.99x10 -7 , 152 respectively; Fig. 4B and Table S7 ), consistent with reports that GATA3, GATA4, and bHLH 153
family TFs bind to methylated DNA outside the cellular context 16 . We compared our findings to 154 published chromatin accessibility data for wild type murine stem cells, which contain normal 155 patterns of DNA methylation, and triple knockouts for DNMT1, DNMT3a, and DNMT3b, in 156 which DNA methylation is abolished 29 . For 5 of 10 tested GATA family TFs, open chromatin 157 regions specific to wild type (i.e., those absent in the triple knockouts) were significantly 158 enriched for their cognate binding sites ( Fig. 4C ), in support of the idea that GATA family TFs 159 preferentially bind methylated DNA in service of their function as "pioneer" factors 30 . In 160 contrast, ETS family TF binding sites were almost universally (38 of 41 tested) enriched in 161
DNMT knockout-specific open chromatin regions. 162
Finally, for mSTARR-seq results to be maximally useful in interpreting DNA 163 methylation-trait associations, we reasoned that they should explain the substantial heterogeneity 164 in DNA methylation-gene expression correlations observed in real populations. To test this 165 possibility, we drew on paired DNA methylation and gene expression data for 1202 human 166 primary monocytes 31 (a cell type closely related to K562s), in which the mean correlation 167 between DNA methylation levels and gene expression at the nearest gene is 0.006 +/-0.189 s.d. 168
(and -0.023 +/-0.304 for CpG sites significantly (FDR<10%) correlated with gene expression; 169 n=81,883 site-gene pairs). Genome-wide, we observed that significant DNA methylation-gene 170 expression correlations in monocytes (FDR<10%) were moderately enriched in mSTARR-seq 171 MD enhancers versus non-MD enhancers (Fisher's exact test, log 2 odds=0.60, p=3.38x10 -4 ). 172
However, for CpG sites that display the canonical negative correlation between DNA 173 methylation and gene expression levels, this relationship was greatly strengthened (log 2 174 odds=1.02, p<10 -15 ). Thus, mSTARR-seq can identify the CpG sites for which DNA methylation 175 variation is most tightly linked to gene expression variation in human primary cells. 176
Together, our findings emphasize substantial variability in the functional relationship 177 between DNA methylation and gene regulation across the genome. Using mSTARR-seq, we 178
show that the magnitude of this relationship is both predictable from genome characteristics and 179 in turn predicts in vivo heterogeneity in real populations. The resulting map of MD regulatory 180 activity thus provides useful guidance for prioritizing DNA methylation-trait associations for 181 further investigation: CpG sites in which DNA methylation levels causally influence gene 182 expression are more likely to be of interest than those that are effectively silent. In addition, we 183 provide support for the hypothesis that pioneer TFs, such as members of the GATA TF family, 184
have a higher affinity for methylated DNA, potentially aiding in their ability to bind condensed 185 chromatin 30 . Indeed, in addition to GATA family TFs, TFs important in development and cell 186 fate, such as FOXA, MyoD, and TCF21, are enriched among MD enhancers with increased 187 activity when methylated. These results raise the interesting possibility that preferential binding 188 of methylated loci could be used to aid in pioneer TF discovery. Finally, mSTARR-seq can be 189 applied as an efficient, high-throughput strategy to map MD activity in a variety of settings, 190
including at specific loci of interest, across cell types, or across cellular environments. 191
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